ALX Oncology - ALXO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $18.83
  • Forecasted Upside: 44.54%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$13.03
▼ -0.35 (-2.62%)

This chart shows the closing price for ALXO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ALX Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALXO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALXO

Analyst Price Target is $18.83
▲ +44.54% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for ALX Oncology in the last 3 months. The average price target is $18.83, with a high forecast of $27.00 and a low forecast of $11.00. The average price target represents a 44.54% upside from the last price of $13.03.

This chart shows the closing price for ALXO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in ALX Oncology. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/21/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/19/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/18/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/16/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/14/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
4/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
3/8/2024Stifel NicolausReiterated RatingBuy ➝ Hold$10.00 ➝ $14.00Low
12/8/2023Jefferies Financial GroupUpgradeHold ➝ Buy$8.00 ➝ $18.00Low
11/14/2023Stifel NicolausLower TargetBuy ➝ Buy$11.00 ➝ $10.00Low
10/11/2023Piper SandlerBoost TargetOverweight ➝ Overweight$8.00 ➝ $11.00Low
10/4/2023UBS GroupLower TargetBuy ➝ Buy$29.00 ➝ $27.00Low
10/4/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$18.00 ➝ $23.00Low
10/3/2023HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $17.50Low
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$18.00Low
8/11/2023Piper SandlerLower TargetOverweight ➝ Overweight$48.00 ➝ $8.00Low
8/11/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$22.00 ➝ $18.00Low
8/11/2023HC WainwrightLower TargetBuy ➝ Buy$30.00 ➝ $16.00Low
7/24/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$22.00Low
4/26/2023Lifesci CapitalReiterated RatingOutperformLow
3/14/2023UBS GroupLower TargetBuy$31.00 ➝ $29.00Low
3/10/2023Credit Suisse GroupLower TargetOutperform$38.00 ➝ $34.00Low
3/10/2023HC WainwrightLower TargetBuy$65.00 ➝ $30.00Low
11/9/2022Cantor FitzgeraldLower Target$32.00 ➝ $22.00Low
11/9/2022HC WainwrightLower TargetBuy$80.00 ➝ $65.00Low
11/8/2022Lifesci CapitalReiterated RatingOutperformLow
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
8/9/2022Cantor FitzgeraldLower Target$60.00 ➝ $32.00Low
8/9/2022Credit Suisse GroupLower TargetOutperform$43.00 ➝ $38.00Low
6/6/2022Stifel NicolausLower Target$35.00 ➝ $16.00High
5/18/2022Piper SandlerLower TargetOverweight$70.00 ➝ $48.00High
5/16/2022HC WainwrightReiterated RatingBuy$80.00Medium
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/14/2022Cantor FitzgeraldLower Target$103.00 ➝ $60.00High
3/1/2022Stifel NicolausLower TargetBuy$60.00 ➝ $36.00Low
3/1/2022HC WainwrightLower Target$100.00 ➝ $80.00High
12/22/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$65.00 ➝ $25.00Low
12/14/2021Credit Suisse GroupLower TargetOutperform ➝ Outperform$83.00 ➝ $53.00Low
11/9/2021Piper SandlerLower TargetOverweight$97.00 ➝ $85.00High
11/4/2021Lifesci CapitalReiterated RatingOutperformMedium
9/29/2021Stifel NicolausInitiated CoverageBuy$106.00Low
8/18/2021Cantor FitzgeraldReiterated RatingOverweightHigh
7/7/2021HC WainwrightReiterated RatingBuyHigh
5/5/2021Credit Suisse GroupInitiated CoverageOutperform$98.00Low
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$98.00Low
4/6/2021UBS GroupInitiated CoverageBuy$96.00Low
2/11/2021Credit Suisse GroupBoost TargetOutperform$62.00 ➝ $98.00Low
2/10/2021HC WainwrightInitiated CoverageBuy$100.00Low
1/6/2021Cantor FitzgeraldBoost TargetOverweight$64.00 ➝ $103.00N/A
12/15/2020Piper SandlerBoost TargetOverweight$78.00 ➝ $97.00Low
12/7/2020Piper SandlerBoost Target$70.00 ➝ $78.00High
11/18/2020Piper SandlerBoost TargetOverweight$55.00 ➝ $70.00Low
9/30/2020Lifesci CapitalReiterated RatingOutperformLow
8/11/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
8/11/2020Jefferies Financial GroupInitiated CoverageBuy$50.00High
8/11/2020Piper SandlerInitiated CoverageOutperform ➝ Overweight$55.00 ➝ $55.00High
8/11/2020Credit Suisse GroupInitiated CoverageOutperform$53.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/17/2023
  • 5 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/17/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/15/2024
  • 9 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 9 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
ALX Oncology logo
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $13.03
Low: $12.51
High: $13.63

50 Day Range

MA: $13.57
Low: $10.72
High: $16.79

52 Week Range

Now: $13.03
Low: $3.94
High: $17.42

Volume

359,332 shs

Average Volume

465,540 shs

Market Capitalization

$653.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of ALX Oncology?

The following Wall Street analysts have issued reports on ALX Oncology in the last year: Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Piper Sandler, Stifel Nicolaus, and UBS Group AG.
View the latest analyst ratings for ALXO.

What is the current price target for ALX Oncology?

6 Wall Street analysts have set twelve-month price targets for ALX Oncology in the last year. Their average twelve-month price target is $18.83, suggesting a possible upside of 44.5%. UBS Group AG has the highest price target set, predicting ALXO will reach $27.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $11.00 for ALX Oncology in the next year.
View the latest price targets for ALXO.

What is the current consensus analyst rating for ALX Oncology?

ALX Oncology currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALXO.

What other companies compete with ALX Oncology?

How do I contact ALX Oncology's investor relations team?

ALX Oncology's physical mailing address is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. The company's listed phone number is 650-466-7125 and its investor relations email address is [email protected]. The official website for ALX Oncology is www.alxoncology.com. Learn More about contacing ALX Oncology investor relations.